Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT06639607 |
| Title | PEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and Recurrent Diffuse Midline Glioma/High-grade Glioma, Medulloblastoma, and Ependymoma (PRiME II) |
| Acronym | PRiME II |
| Recruitment | Not yet recruiting |
| Gender | both |
| Phase | Phase Ib/II |
| Variant Requirements | No |
| Sponsors | Washington University School of Medicine |
| Indications | |
| Therapies | |
| Age Groups: | child | adult |
| Covered Countries | USA |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| Washington University School of Medicine | Saint Louis | Missouri | 63110 | United States | Details | |
| Duke University Medical Center | Durham | North Carolina | 27710 | United States | Details | |
| MD Anderson Cancer Center | Houston | Texas | 77030 | United States | Details |